Atreca Moves Toward Final Liquidation as CVRs Hinge on Immunome Agreement

Atreca, the biotechnology firm, is in the final phase of its wind-down and formal dissolution. Shareholders had already endorsed this course of action in May 2024, and the company’s operating core effectively ceased long before. For former investors, the focus now centers on whether any remaining rights can be monetized.

• Liquidation dividend of $0.05 per share paid in late December 2024.
• Nasdaq trading ended in mid-2024 following the delisting.
• The sale of 28 antibody programs to Immunome has been completed.

CVRs and Potential Payments

The core of the remaining claims revolves around Contingent Value Rights (CVRs). These non-transferable rights were issued to shareholders as part of the dissolution plan and offer the possibility of additional payments if the Immunome-purchased drug candidates achieve certain clinical milestones. Whether these CVRs will ever deliver significant cash inflows remains a key question.

Of particular note is the APN-497444 program, an antibody-drug conjugate aimed at gastrointestinal cancers. Immunome has already paid an upfront for the portfolio of 28 antibodies. Any further payments now depend on the clinical success of the research that Atreca could not fund due to resource constraints.

Should investors sell immediately? Or is it worth buying Atreca?

End of Market Presence

The liquidation marks the end of a lengthy decline. The stock was removed from Nasdaq in March 2024 for not meeting the minimum bid price requirements, and trading on the over-the-counter market ceased on June 14, 2024.

The setback in Atreca’s development pipeline contributed to its downfall. While programs like ATRC-101 reached Phase 1b, others such as ATRC-301 were halted in preclinical stages due to toxicity concerns. In a 2026 market environment shaped by growth among large players like AstraZeneca, which still demands efficient capital allocation, Atreca was unable to secure new financing.

No further routine liquidation payouts are planned. The remaining potential value for former investors is entirely tied to the success of the Immunome-led research initiatives.